Results 21 to 30 of about 9,892 (240)

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study

Patient Preference and Adherence, 2021
Holger Schirutschke, Peter Gross, Alexander Paliege, Christian Hugo University Hospital Carl Gustav Carus at the Technische, Universität Dresden, Department of Internal Medicine III, Division of Nephrology, Dresden, GermanyCorrespondence: Holger ...
Schirutschke H, Gross P, Paliege A, Hugo C   +3 more
doaj  

Effectiveness of Tolvaptan Treatment in Hyponatremic Patients

Turkish Journal of Internal Medicine, 2020
Objective: Non-peptide vasopressin receptor antagonists (vaptans) are effective at increasing sodium in euvolemic and hypervolemic states and appear safe. We aimed to evaluate the efficacy of tolvaptan in euvolemic or hypervolemic hyponatremic patients.
Mehmet Fethullah Aydın, Alparslan Ersoy, Mahmut Yavuz, Emel Isıktas Sayılar, Yavuz Ayar   +4 more
doaj   +1 more source

Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction

International Journal of Cardiology: Heart & Vasculature, 2018
Background: Tolvaptan is a vasopressin type 2 receptor antagonist used in heart failure (HF) with refractory diuretic resistance. However, since tolvaptan is also ineffective in some HF patients with reduced ejection fraction (HFrEF), the identification ...
Shinichi Nonin, Shinichi Iwata, Asahiro Ito, Soichiro Tamura, Ryoko Kitada, Yu Kawai, Sera Ishikawa, Atsushi Doi, Akihisa Hanatani, Minoru Yoshiyama   +9 more
doaj   +1 more source

Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice

European Journal of Histochemistry, 2022
Heart failure (HF) is often complicated by renal dysfunction. Tolvaptan and valsartan are two well-known agents for the treatment of HF. However, the role of tolvaptan/valsartan combination on HF with renal dysfunction remains unclear.
Fengqin Yan, Hong Zhu, Yingxia He, Qinqin Wu, Xiaoyu Duan   +4 more
doaj   +1 more source

Hyponatremia : Special Considerations in Older Patients [PDF]

, 2014
Acknowledgments Roy L.
Clarke, Jennifer M, Cumming, Kirsten, Myint, Phyo K, Soiza, Roy L, Wood, Karen M   +4 more
core   +2 more sources

Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD)

Therapeutic Advances in Endocrinology and Metabolism, 2023
The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonist, leads through aquaresis to an increase in serum sodium
Ploutarchos Tzoulis, Gregory Kaltsas, Stephanie E. Baldeweg, Pierre-Marc Bouloux, Ashley B. Grossman   +4 more
doaj   +1 more source

Improving Postdischarge Outcomes in Acute Heart Failure [PDF]

, 2018
The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P., Antohi, Elena-Laura, Butler, Javed, Chioncel, Ovidiu, Collins, Sean P., Iliescu, Vlad Anton, Maggioni, Aldo P., Mebazaa, Alexandre, Pang, Peter S.   +8 more
core   +1 more source

Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway. [PDF]

, 2017
The store-operated calcium entry (SOCE) pathway is an important route for generating cytosolic Ca2+ signals that regulate a diverse array of biological processes.
Rahman, Saifur, Rahman, Taufiq
core   +2 more sources

Tolvaptan Attenuates Left Ventricular Fibrosis After Acute Myocardial Infarction in Rats

Journal of Pharmacological Sciences, 2013
Tolvaptan, a non-peptide V2-receptor antagonist, is a newly developed diuretic agent. Recently, we reported that tolvaptan has diuretic as well as anti-inflammatory and anti-fibrotic actions in chronic heart failure.
Takanori Yamazaki, Yasuhiro Nakamura, Masayuki Shiota, Mayuko Osada-Oka, Hiroyuki Fujiki, Akihisa Hanatani, Kenei Shimada, Katsuyuki Miura, Minoru Yoshiyama, Hiroshi Iwao, Yasukatsu Izumi   +10 more
doaj   +1 more source

Renoprotective effect of tolvaptan in patients with new‐onset acute heart failure

ESC Heart Failure, 2020
Aims Although tolvaptan has been reported to prevent worsening renal function (WRF) in patients with advanced acute heart failure (AHF), evidence regarding the effect of tolvaptan on renal function in patients with new‐onset AHF is not available.
Hiromi Kin, Koichiro Matsumura, Yoshihiro Yamamoto, Kenichi Fujii, Munemitsu Otagaki, Hiroki Takahashi, Haengnam Park, Kei Yoshioka, Mitsuru Yokoi, Tetsuro Sugiura, Ichiro Shiojima   +10 more
doaj   +1 more source